Technologies Vie for Dominance

Courtesy of Bio-Rad Laboratories  AUTOMATING DISCOVERY: Two-dimensional gel-based proteomics is traditionally derided for its technical difficulty, low-throughput, and lack of reproducibility. Instrument manufacturers have fired back with a range of automated and integrated options. Shown here is the ProteomeWorks product line. Thierry Rabilloud has been doing proteomics since long before the word proteome was even coined. For years Rabilloud, currently at the Atomic Energy Commission Re

Written byJeffrey Perkel
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Thierry Rabilloud has been doing proteomics since long before the word proteome was even coined. For years Rabilloud, currently at the Atomic Energy Commission Research Center in Grenoble, France, used two-dimensional gel electrophoresis (2-DE) to break complex protein mixtures down into their component parts, purified individual proteins that interested him, and then sent these out for identification by mass spectrometry (MS). But at this point his research hit a bottleneck: the MS facility could accept only a few samples at a time, because the sample processing procedure was so labor-intensive. Then the MS lab acquired robots to automate the processing steps, and the bottleneck disappeared. "Before we were sending in maybe 10 spots. It was a lot of work," he recalls. "Now we can send 50 spots. That's a piece of cake."

Rabilloud's experience is not unique. Traditionally, the 2-DE-based workflow is labor-intensive, technically challenging, difficult to reproduce, and low-throughput. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies